Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Phase 2

Completed

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Methotrexate
Drug: Rituximab
Drug: Cytarabine
Drug: Thiotepa
Drug: liposomial cytarabine
Drug: Etoposide
Drug: Ifosfamide
Drug: Carmustine
Radiation: whole brain radiotherapy

First Posted Date: 2014-12-31

Last Posted Date: 2024-07-29

Lead Sponsor: International Extranodal Lymphoma Study Group (IELSG)

Target Recruit Count: 76

Registration Number: NCT02329080

Locations: 🇮🇹
IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
🇮🇹
Villa Sofia - Cervello, Palermo, Italy
🇨🇿
Facultni nemocnice, Brno, Czechia

and more 33 locations

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Phase 3

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Bone Marrow
Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
Metastatic Ewing Sarcoma
Metastatic Malignant Neoplasm in the Bone
Metastatic Malignant Neoplasm in the Lung
Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Etoposide Phosphate
Radiation: External Beam Radiation Therapy
Drug: Ifosfamide
Biological: Ganitumab
Radiation: Stereotactic Radiosurgery
Procedure: Therapeutic Surgical Procedure
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2014-12-03

Last Posted Date: 2024-12-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 312

Registration Number: NCT02306161

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States

and more 313 locations

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: GMI-1271
Drug: Mitoxantrone
Drug: Etoposide
Drug: Idarubicin
Drug: Cytarabine

First Posted Date: 2014-12-03

Last Posted Date: 2019-05-17

Lead Sponsor: GlycoMimetics Incorporated

Target Recruit Count: 91

Registration Number: NCT02306291

Locations: 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 5 locations

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities

Interventions: Drug: mitoxantrone hydrochloride
Drug: selinexor
Drug: etoposide
Drug: cytarabine
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-11-24

Last Posted Date: 2023-06-15

Lead Sponsor: Alice Mims

Target Recruit Count: 23

Registration Number: NCT02299518

Locations: 🇺🇸
The State Ohio University Comprehensive Cancer Center, Columbus, Ohio, United States

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

Phase 2

Completed

Conditions: Hodgkin Lymphoma

Interventions: Drug: brentuximab vedotin
Drug: Cyclophosphamide
Drug: Adriamycin
Drug: Oncovin
Drug: Bleomycin
Drug: Etoposide
Drug: Procarbazine
Drug: Prednisone
Drug: G-CSF
Radiation: 30 Grays

First Posted Date: 2014-11-21

Last Posted Date: 2021-07-26

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 40

Registration Number: NCT02298283

Locations: 🇫🇷
CH Sud Francilien, Corbeil-Essonnes, France
🇫🇷
Hôpital André Mignot, Le Chesnay, France
🇫🇷
Centre Léon Bérard, Lyon, France

and more 27 locations

Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Veliparib
Drug: Etoposide
Drug: Placebo

First Posted Date: 2014-11-13

Last Posted Date: 2020-05-14

Lead Sponsor: AbbVie

Target Recruit Count: 221

Registration Number: NCT02289690

Locations: 🇨🇿
Vitkovicka nemocnice a. s. /ID# 149839, Ostrava, Czechia
🇰🇷
Chonnam National University Hwasun Hospital /ID# 153188, Jeonnam, Korea, Republic of
🇺🇸
Georgia Regents University /ID# 148567, Augusta, Georgia, United States

and more 59 locations

Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery

Phase 2

Active, not recruiting

Conditions: Recurrent Non-small Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer

Interventions: Radiation: hypofractionated radiation therapy
Drug: cisplatin
Drug: etoposide
Radiation: 3-dimensional conformal radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2014-10-13

Last Posted Date: 2024-08-23

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT02262325

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Phase 1

Completed

Conditions: CLASSICAL HODGKIN LYMPHOMA

Interventions: Drug: Brentuximab Vedotin
Drug: Etoposide
Drug: Soludomerin
Drug: Cisplatin
Drug: Ara C

First Posted Date: 2014-09-18

Last Posted Date: 2019-04-24

Lead Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Target Recruit Count: 67

Registration Number: NCT02243436

Locations: 🇪🇸
Hospital General Universitario Gregorio Marañon, Madrid, Spain
🇪🇸
Hospital Clínico de Valencia, Valencia, Spain
🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain

and more 11 locations

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Phase 1

Withdrawn

Conditions: Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease
Primary Effusion Lymphoma

Interventions: Drug: Pomalidomide
Drug: Rituximab
Drug: Prednisone
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide

First Posted Date: 2014-08-29

Last Posted Date: 2018-08-31

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT02228512

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Recurrent Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Interventions: Drug: Brentuximab Vedotin
Drug: Carboplatin
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-08-28

Last Posted Date: 2024-02-15

Lead Sponsor: University of Washington

Target Recruit Count: 45

Registration Number: NCT02227199

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy